Fox Factory Debuts First Team in Rebelle Rally 2024

DULUTH, Ga., Sept. 19, 2024 (GLOBE NEWSWIRE) — Fox Factory Holding Corp. (Nasdaq: FOXF) announced it is fielding its first team to compete in the Rebelle Rally, the longest competitive off-road navigation rally in the United States and the first women’s endurance off-road rally in America. Kristen Matlock, professional driver and FOX-supported athlete, along with […]

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), taking place September 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta. The event

Evaxion launches improved AI-Immunology(TM) platform for vaccine antigen prediction

The new version 5.0 of the AI model EDEN(TM) features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion’s ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology(TM)

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce the appointment of Riccardo Carbucicchio as

EDAP and Avenda Health Launch World’s First AI-Assisted Focal One(R) Robotic HIFU Procedures

First Unfold AI(R)-Assisted Focal One procedures successfully performed at the UCLA School of Medicine FDA-cleared Unfold AI enables urologists to provide tailored, patient-specific Robotic HIFU ablation for prostate cancer patients EDAP and Avenda Health to present Unfold AI-Assisted Focal One simulated procedures at the 2024 Joint Meeting of the Focal Therapy Society & Society of

Canadian Investment Regulatory Organization Trading Halt – TIM.X

The following issues have been halted by CIRO: Company: QNB Metals Inc. CSE Symbol: TIM.X All Issues: Yes Reason: Pending review of fundamental change by listing exchange Halt Time (ET):7:47 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented

Pro Padel League: The Padel competition in the USA arrives on Padel Time TV

We are thrilled to announce the exclusive broadcast of the Pro Padel League, one of the most anticipated events in the world of padel, on Padel Time TV. This collaboration marks a major milestone for the channel, reinforcing its commitment to promoting the sport and providing exceptional coverage for its fans. The Pro Padel League

eCential Robotics Appoints Experienced Leadership Team to Drive U.S. Market Expansion

eCential Robotics, a growth company transforming bone surgery by designing and manufacturing an open robotic and navigation system with unique capabilities, is pleased to announce the addition of Lisa Jacobs and Matthieu Ville to its leadership team. These strategic hires come as part ofeCential Robotics’ commitment to accelerating its growth and innovation in the U.S.

Anytime AI CEO Presents at TEDx, Bringing Legal AI to the Main Stage

In a groundbreaking first for TEDx, Legal Artificial Intelligence (AI) took center stage as Dr. Lingfei (Teddy) Wu, CEO and co-founder ofAnytime AI, delivered a captivating talk at TEDxCSTU on July 28th, 2024. Dr. Wu’s talk, titled ‘AI in Law: A Mandate, Not an Option,’ marked a pivotal moment in the legal industry, showcasing how

QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy

QRL-101 is the only Kv7.2/7.3 ion channel opener being actively studied for the treatment of hyperexcitability-induced disease progression in ALS Kv7.2/7.3 is a clinically validated target to regulate the hyperexcitable state in epilepsy Company initiates exploratory Phase 1 proof-of-mechanism study in healthy volunteers to characterize the potential anti-seizure effects of QRL-101 QurAlis Corporation (“QurAlis”), a

Scroll to Top